Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
04/2005
04/05/2005US6875789 Pyrazole-derived kinase inhibitors and uses thereof
04/05/2005US6875779 Cyclooxygenase inhibitor
04/05/2005US6875777 Compounds
04/05/2005US6875775 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
04/05/2005US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
04/05/2005US6875765 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family
04/05/2005US6875570 Proteins and nucleic acids encoding same
03/2005
03/31/2005WO2005028491A1 Epimeredi glycoside a, the formulation containing thereof and their preparation method
03/31/2005WO2005028476A1 Substituted indolizine 1,2,3,6,7,8 derivatives, fgfs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives
03/31/2005WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
03/31/2005WO2005028438A1 Novel piperidine derivative
03/31/2005WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor
03/31/2005WO2005027933A1 Unsaturated phosphatidylcholines and uses thereof
03/31/2005WO2005027931A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
03/31/2005WO2005027930A1 2-alkylene-19-nor-vitamin d derivatives for the treatment of osteosarcoma
03/31/2005WO2005027929A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
03/31/2005WO2005027927A1 2-alkylidene-19-nor-vitamin d derivatives for enhancement of peak bone mass in adolescence
03/31/2005WO2005027926A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bone morphogenetic protein
03/31/2005WO2005027925A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
03/31/2005WO2005027924A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
03/31/2005WO2005027921A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
03/31/2005WO2005027920A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
03/31/2005WO2005027919A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
03/31/2005WO2005027918A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
03/31/2005WO2005027917A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
03/31/2005WO2005027916A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
03/31/2005WO2005027915A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
03/31/2005WO2005027913A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
03/31/2005WO2005027883A1 Gsk-3 beta inhibitors in the treatment of bone-related diseases
03/31/2005WO2005027882A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
03/31/2005WO2005012232A3 Hydrazide derivatives as prostaglandin receptors modulators
03/31/2005WO2004098617A3 Controlled release composition containing a strontium salt
03/31/2005WO2004010951A8 Method of treating tumors
03/31/2005WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/31/2005WO2003018756A3 Methods for preparing purified prostaglandin e synthase
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070706 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070699 Nucleotide sequences coding low density lipoprotein receptor-related protein 5 for use as tools in diagnosis and treatment of osteoporosis; high bone mass and bone disorders
03/31/2005US20050070694 Antagonistic anti-htnfsf13b human antibodies
03/31/2005US20050070692 Anti-interleukin-1 beta analogs
03/31/2005US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders
03/31/2005US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
03/31/2005US20050070574 Novel compounds
03/31/2005US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors
03/31/2005US20050070566 Imidazoquinoline derivatives
03/31/2005US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions
03/31/2005US20050070557 Use of pyrazolo(4,3-d)pyrimidine derivatives; for example, 5-(3-chloro-benzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
03/31/2005US20050070555 Aroyl pyridinones
03/31/2005US20050070535 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder
03/31/2005US20050070530 Dipeptidyl peptidase inhibitors
03/31/2005US20050070512 Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
03/31/2005US20050070500 Method of modulating release of saccharides and uses thereof
03/31/2005US20050070491 Immunostimulatory nucleic acid molecules
03/31/2005US20050070485 Phenylalanine derivatives
03/31/2005US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference
03/31/2005US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor
03/31/2005US20050069878 Proteins associated with cell growth, differentiation, and death
03/31/2005US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders.
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069569 Osteocalcin; enzyme inhibitors; promote bone, teeth growth; administering Dna gene
03/31/2005US20050069547 Binding protein; therapy for bone tumors
03/31/2005CA2551037A1 Novel piperidine derivative
03/31/2005CA2539741A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
03/31/2005CA2539361A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
03/31/2005CA2539359A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
03/31/2005CA2539358A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
03/31/2005CA2539357A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
03/30/2005EP1517988A2 Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure
03/30/2005EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
03/30/2005EP1517914A2 9-alpha-substituted estratrienes as selectively active estrogen
03/30/2005EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
03/30/2005EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
03/30/2005EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
03/30/2005EP1517704A1 Use of antibodies against flt-1 for the treatment of osteoporosis
03/30/2005EP1517703A1 Placental growth factor as a target for the treatment of osteoporosis
03/30/2005EP1517688A2 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
03/30/2005EP1517676A1 Oral dosage forms comprising fenofibrate
03/30/2005EP1438289B1 Indole derivatives as cox ii inhibitors
03/30/2005EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
03/30/2005EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists
03/30/2005EP1224163B1 Use of carbonylamino derivatives against cns disorders
03/30/2005EP1181035B1 Substantially oil-free cyclosporin compositions
03/30/2005EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors
03/30/2005CN1602425A Therapeutic and diagnostic uses of antibody specificity profiles
03/30/2005CN1602317A Angiopoietin-2 specific binding agents
03/30/2005CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase
03/30/2005CN1602307A Substituted 6h-dibenzo[c, h]chromenes as estrogenic agents
03/30/2005CN1602304A Deuterated substituted dihydrofuranones and medicaments containing these compounds
03/30/2005CN1602190A Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
03/30/2005CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution
03/30/2005CN1602159A Composition for promotion of bone growth and maintenance of bone health
03/30/2005CN1602158A Food or pet food composition containing plant extract for bone health
03/30/2005CN1600370A New chemical medicine in small molecule in use for curing dysmenorrhea and ache of bad rheumatoid arthritis
03/30/2005CN1600350A Capsule of activating the channels for cervical vertebrae
03/30/2005CN1600343A External remedy for curing scapulohumeral periarthritis
03/30/2005CN1600341A Medication for curing lumbar intervertebral disc protrusion
03/30/2005CN1600340A External remedy for curing pain of lower back and leg
1 ... 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 ... 820